BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Q&A

Placental Stem Cells – The Rise of Placental Blood & Tissue Applications

March 18, 2018 By Cade Hildreth (CEO) 3 Comments

In this interview with Dr. Ornella Parolini, Director of the E. Menni Research Center in Italy, we discussed her pioneering research on human placental stem cells. Her research is focused on the immunomodulatory and anti-inflammatory properties of amniotic and chorionic membrane cells. She is also President of the International Placenta Stem Cell Society (IPLASS), making her a globally recognized expert.

In addition to Dr. Robert Harari who holds a wide range of placental stem cell patents, Dr. Parolini is one of the world’s leading experts on placental stem cells and their therapeutic applications.

In this article:

  • Definition of Placental Stem Cells
  • Interview with Placental Stem Cell Expert, Dr. Parolini
  • Placental Stem Cell Advantages
  • International Placental Stem Cell Society
  • Clinical Applications of Placental Stem Cells

[Read more…]

Filed Under: Cord Blood, Interviews Tagged With: cord blood, hematopoietic, perinatal stem cells, placental stem cells, Q&A

Setting the Standard in Adipose-Derived Stem Cell Applications

August 15, 2016 By Cade Hildreth (CEO) Leave a Comment

Okyanos, Stem Cell Therapy
Matthew Feshbach, CEO and Co-Founder of Okyanos
Matthew Feshbach, CEO and Co-Founder of Okyanos

This article is part two of my interview with Matthew Feshbach, CEO and Co-Founder of Okyanos (pronounced “Oh – key – AH – nos”). Founded in 2011, Okyanos specializes in treating patients with chronic, degenerative conditions. Located in Freeport, Grand Bahama, just 55 miles from the United States, Okyanos Cell Therapy combines a blend of stem and regenerative cells derived from a patient’s own adipose (fat) tissue.

Treatment is performed in their state-of-the-art surgical center by a team of U.S. licensed medical doctors. Okyanos is also fully licensed under the Bahamas Stem Cell Therapy and Research Act and adheres to U.S. surgical center standards.

Using technology from Cytori Therapeutics, the company offers a highly characterized cellular product that is administered via a robust protocol by a renowned medical team within a world-class facility. It is my opinion, that Okyanos is a company that is setting the standard for others practicing cellular therapy with adipose-derived stem and regenerative cells.

Enjoy this second half of the interview. If you haven’t read it yet, click here to view Part 1. [Read more…]

Filed Under: Adipose SCs, Interviews, MSCs, Stem Cells Tagged With: adipose-derived stem cells, cell therapy, Matthew Feshbach, mesenchymal stem cells, Okyanos, Q&A

Improving Access to Donor- and Disease-Specific Stem Cells – Interview with Alec Lee of Extem Bioscience

January 17, 2016 By Cade Hildreth (CEO) Leave a Comment

Q&A Interview with Alec Lee of Extem Biosciences

Extem BioscienceThis is an interview with Alec Lee, Head of Business Development at Extem Bioscience, an innovative stem cell company that has developed a new device and process to purify and expand adult stem cells in greater numbers.

The company is focused on the isolation, rapid purification, and expansion of adult mesenchymal stem cells (MSCs). Enjoy these insights into Extem’s future strategies and directions.

Interview with Alec Lee of Extem Bioscience

Cade Hildreth: How and when was Extem founded?

Alec Lee: Extem was founded in 2014 in Vancouver, British Columbia, and now based in San Francisco, California.

Cade Hildreth: How was your team of founders formed?

Alec Lee: The founders – Mardonn, Darson, and Alec – were all alumni of the Biotechnology Program at the University of British Columbia. Mardonn Chua (CEO) conceived the idea as a researcher at Columbia University, as a way to enable his lab to regularly work with primary stem cells.

Darson (CSO) is responsible for experimental design and process development. His experience working as a QA and QC Inspector in industry enables the team to uphold the level of product quality customers expect.

Alec Lee is a Harvard Business School student and oversees the business development and strategic play of the venture.

Mike Bowles (Machine Learning) builds our learning algorithms. He was the co-founder of Com 21, iBeam, and was professor of Machine Learning – Control and Estimation Theory at MIT.

Cade Hildreth: What is the core technology on which Extem is based?

Alec Lee: The core technology is based on two parts – first, the rapid purification and expansion of adult stem cells without genetic manipulation, and second, the development of analytical models of stem cell differentiation based on machine learning algorithms.

On the production end, Extem has developed a new device and process to purify and expand adult stem cells, specifically MSCs at greater numbers. This allows us to provide researchers in academia and industry with improved access to donor- and disease-specific stem cells.

Cade Hildreth: How does Extem differ from other mesenchymal stem cell (MSC) companies?

Alec Lee: Extem’s technology is comprised of a production core and computational biology core. While traditional MSC (and other stem cell) companies offer only marginal improvements in stem cell growth, we are the first stem cell company developing predictive models of stem cell differentiation – i.e. being able to predict, to a certain degree, how well a donor or patient’s cells form into bone or cartilage tissue.

Extem Bioscience

We believe that our two-core technology provides a more robust approach to evaluating the efficacy of MSCs not just for basic research, but also for pre-clinical drug development. At the outset, our system provides our clients with therapeutic-centric data.

Cade Hildreth: Have you filed for or are you pursuing intellectual property (IP) positions?

Alec Lee: Yes, the company has filed a provisional patent on our production process. We are currently developing IP for our machine learning systems.

Cade Hildreth: What are your near-term (3-5 year) goals?

Alec Lee: We have three main goals in the near term: first, to expand our bank of stem cells to 100 donors, second, to complete the next version of our machine learning algorithms for osteogenic, adipogenic, and chondrogenic differentiation, and third, to work with clinicians in assessing the predictive power of our algorithms in stem cell-based therapeutic applications.

Cade Hildreth: Do you anticipate seeking out partnerships or investors for Extem Bioscience?

Alec Lee: Yes, we have raised venture capital to fund initial operations and anticipate raising further investment for future R&D.

Cade Hildreth: Do you foresee yourselves staying a MSC-specific company or expanding into other stem cell types?

Alec Lee: Expanding to different stem cell types (e.g. hematopoietic stem cells and even induced pluripotent stem cells) is on our timeline. We have specifically developed our tech to be tractable for other stem cell types.

Cade Hildreth: Thank you for the honor of doing this interview and for sharing insights into your innovative MSC products.

To learn more about Extem Biosciences, visit www.ExtemBio.com or connect with Alec Lee on LinkedIn.

Filed Under: Interviews, MSCs, Stem Cells Tagged With: Extem Biosciences, interview, market news, mesenchymal stem cells, Q&A, stem cells

Exclusive Interviews with Stem Cell Leaders – Accellta, Gamida Cell, and More

January 11, 2016 By Cade Hildreth (CEO) Leave a Comment

Exclusive Stem Cell Interviews - Accellta, Gamida Cell, and More

We just released exclusive question and answer (Q&A) interviews with the CEO and Head of Business Development for Accellta, a revolutionary stem cell culture company. Accellta is introducing a paradigm shift to the stem cell marketplace, announcing that it can quickly, efficiently, and cost-effectively grow massive quantities of clinical grade cells in xeno-free, feeder-free culture using large bioreactors.

With this revolutionary technology, the company has already already secured licensing deals with major players across the stem cell products marketplace, including Thermo Fisher Scientific, STEMCELL Technologies, and Miltenyi Biotec. [Read more…]

Filed Under: Stem Cells Tagged With: interviews, market news, Q&A, stem cells

Top 5 Stem Cell Interviews of 2015

December 27, 2015 By Cade Hildreth (CEO) Leave a Comment

Top 5 Stem Cell Interviews of 2015

As 2016 approaches, it is an important time to look back on 2015 and all that the year entailed for stem cell advances. During 2016, I was honored to have interviewed a number of key thought leaders in the stem cell space, including the CEO of the largest dental stem cell company in the world (Tony Veverka of BioEden), Chief Business Officer for a company creating the world’s largest blood cell repository for iPSC production (James Lovgren of ORIG3N), and VP of Research and Development for one of the most innovative companies operating within the stem cell sector (Dr. Grynspan of Stem Cell Medicine).

Throughout 2015, my team and I conducted dozens of other interviews as well, with stem cell executives, investors, and researchers. These interviews were published on our stem cell industry blog and also  informed market projections for BioInformant’s stem cell and cord blood market intelligence reports. [Read more…]

Filed Under: HSCs, iPS Cells, MSCs, Stem Cells Tagged With: Accellta, Auxocell, BioEden, interview, Orig3n, perinatal stem cells, Q&A

  • 1
  • 2
  • Next Page »

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    Rated 0 out of 5
    $297
  • U.S. Cord Blood Banking Survey Cord Blood Banking Survey of U.S. Parents [2017]
    Rated 0 out of 5
    $197
  • Exosome Companies 2020 Global Database of Exosome Companies
    Rated 0 out of 5
    $149 $97
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.